Search

Your search keyword '"Sturgeon, Catharine M."' showing total 147 results
Start Over Author "Sturgeon, Catharine M."
147 results on '"Sturgeon, Catharine M."'

3. Contributors

Author

Ahmed, S. Faisal, primary, Ah-Moye, David, additional, Arya, Roopen, additional, Ayling, Ruth M., additional, Badminton, Michael N., additional, Bayly, Graham R., additional, Belsey, Sarah, additional, Berry, Robin, additional, Bindoff, Laurence A., additional, Bjarnason, Ingvar T., additional, Bomford, Adrian, additional, Bruce, Helen, additional, Carragher, Fiona, additional, Chadwick, Carrie, additional, Champion, Mike, additional, Cundy, Timothy, additional, Davies, Ceinwen, additional, Davies, Teifion, additional, Davies, Zoe, additional, Dawnay, Anne, additional, Dayan, Colin M., additional, Dear, James W., additional, East, James E., additional, Elder, George H., additional, Flanagan, Robert J., additional, Frewin, Rebecca, additional, Galtrey, Clare M., additional, Gillen, Philip, additional, Goodall, Roberta, additional, Goody, Joanne, additional, Grey, Andrew, additional, Hallworth, Mike, additional, Hart, Paul, additional, Hayward, Peter, additional, Howlett, Trevor A., additional, Htut, Min, additional, Jones, Jeremy G., additional, Keir, Geoffrey, additional, Labib, Mourad H., additional, Lapsley, Marta, additional, Launiainen, Terhi, additional, Levy, Miles J., additional, Loughrey, Clodagh M., additional, McNeilly, Jane D., additional, Makanjuola, David, additional, Marshall, William J., additional, Miell, John, additional, Okosieme, Onyebuchi E., additional, Paviour, Dominic C., additional, Penney, Michael D., additional, Rees, David C., additional, Reid, Ian R., additional, Riches, Pamela G., additional, Ross, Leslie D., additional, Seetho, Ian W., additional, Sheldon, Joanna, additional, Sherwood, Roy A., additional, Sturgeon, Catharine M., additional, Taylor, Peter, additional, Wassif, Wassif S., additional, Wheeler, Rachel D., additional, Wilding, John P.H., additional, Wile, David B., additional, and Young, Ian S., additional

Published
2014
Full Text
View/download PDF

5. List of Contributors

Author

Alcocer, Marcos, primary, Amenhotep, Zane D., additional, Andersen, Philip R., additional, Armbruster, David, additional, Backus, John, additional, Binder, Steven R., additional, Bowsher, Ronald R., additional, Brennan, Catherine A., additional, Burnham, Carey-Ann D., additional, Chan, Daniel W., additional, Chapman, Richard S., additional, Christofides, Nic D., additional, Clark, Penny M., additional, Dent, Alastair H., additional, Dessi, John L., additional, Devare, Sushil G., additional, Doern, Christopher, additional, Duffin, Gordon, additional, Duffy, David C., additional, Dunbar, Sherry A., additional, Dunn, John R., additional, Evans, Katy, additional, Faye, Sherry, additional, Fleming, Richard, additional, Fraser, William, additional, French, Deborah, additional, Gimzewski, James K., additional, Gore, Angela, additional, Granger, Douglas A., additional, He, Jianwen, additional, Hindmarsh, Peter, additional, Hoffmeyer, Michaela R., additional, Hofmann, Oliver, additional, Huckle, David, additional, Hutchings, Alun, additional, Isler, Jennifer, additional, John, Rhys, additional, Johnson, Sara B., additional, Karlsson, Robert, additional, Kaul, Ravi, additional, Keren, David F., additional, Koshy, Thomas I., additional, Kricka, Larry J., additional, Lamb, Kelly J., additional, Laterza, Omar F., additional, Lawrence, John C., additional, Leathers, Valerie L., additional, Leith, Katherine M., additional, Liddell, Eryl, additional, McDonald, Timothy J., additional, Metzar, Jean, additional, Nichols, James H., additional, Nowatzke, William L., additional, O’Connor, Thomas P., additional, O’Farrell, Brendan, additional, Out, Dorothée, additional, Park, Jason Y., additional, Parker, Simon P., additional, Perry, Leslie, additional, Price, Christopher P., additional, Quinn, Frank A., additional, Ramachandran, Radha, additional, Rattle, Simon, additional, Reed, Jason, additional, Renshaw, Simon, additional, Rissin, David M., additional, Røseth, Arne, additional, Routledge, Philip A., additional, Rumsby, Gill, additional, Sailstad, Jeffrey M., additional, Sarfati, Patrice D., additional, Sarli, Amy, additional, Self, Colin, additional, Shah, Dinesh O., additional, Sheehan, Chris, additional, Sokoll, Lori J., additional, Spencer, Kevin, additional, Stewart, James L., additional, Street, Theresa, additional, Sturgeon, Catharine M., additional, Sunwoo, Hoon H., additional, Thompson, Stephen, additional, Tiplady, Sarah M., additional, Turnbull, Maggie, additional, Ullman, Edwin F., additional, Weeks, Ian, additional, Wheeler, Mike, additional, Wild, David G., additional, Wilson, David H., additional, Workman, Erwin, additional, Wu, Alan H.B., additional, Ardern, John, additional, Armstrong, Alan S., additional, Babson, Arthur L., additional, Blockx, Pierre, additional, Brandt, Doug, additional, Buechler, Kenneth F., additional, Chard, Tim, additional, Colston, Kay W., additional, Danielson, Susan J., additional, Davies, Christopher, additional, Dawson, Derek, additional, Dille, Bruce J., additional, Donahoe, Theresa, additional, Ekins, Roger, additional, Evans, Gareth, additional, Ford, Kent, additional, Hilborn, David A., additional, Kusnezow, Wlad, additional, Martin, Manuella, additional, McLellan, W.N., additional, Medbak, Sami, additional, Mushahwar, Isa K., additional, Myers, Mary Beth, additional, Preece, Michael, additional, Pringle, Jane, additional, Rilvën, Mats, additional, Ritchie, Robert, additional, Safford, John W., additional, Smith, Mari G., additional, Spencer, Carole A., additional, Stevenson, John C., additional, Suresh, Mavanur R., additional, Waters, Harry, additional, Wilde, Colin, additional, and Yman, Lars, additional

Published
2013
Full Text
View/download PDF

12. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer

Author

Sölétormos, György, Duffy, Michael J., Othman Abu Hassan, Suher, Verheijen, René H.M., Tholander, Bengt, Bast, Robert C., Gaarenstroom, Katja N., Sturgeon, Catharine M., Bonfrer, Johannes M., Petersen, Per Hyltoft, Troonen, Hugo, CarloTorre, Gian, Kanty Kulpa, Jan, Tuxen, Malgorzata K., and Molina, Raphael

Subjects
Ovarian Neoplasms, Societies, Scientific, endocrine system diseases, Monitoring, HE4, Carcinoma, Ovarian Epithelial, Middle Aged, Prognosis, female genital diseases and pregnancy complications, Ovarian Cancer, Diagnosis, Differential, CA125, CA-125 Antigen, Practice Guidelines as Topic, Screening, Biomarkers, Tumor, Humans, Differential diagnosis, Female, Neoplasms, Glandular and Epithelial, Algorithms, Aged, Follow-Up Studies
Abstract

Objective To present an update of the European Group on Tumor Markers guidelines for serum markers in epithelial ovarian cancer. Methods Systematic literature survey from 2008 to 2013. The articles were evaluated by level of evidence and strength of recommendation. Results Because of its low sensitivity (50–62% for early stage epithelial ovarian cancer) and limited specificity (94–98.5%), cancer antigen (CA) 125 (CA125) is not recommended as a screening test in asymptomatic women. The Risk of Malignancy Index, which includes CA125, transvaginal ultrasound, and menopausal status, is recommended for the differential diagnosis of a pelvic mass. Because human epididymis protein 4 has been reported to have superior specificity to CA125, especially in premenopausal women, it may be considered either alone or as part of the risk of ovarian malignancy algorithm, in the differential diagnosis of pelvic masses, especially in such women. CA125 should be used to monitor response to first-line chemotherapy using the previously published criteria of the Gynecological Cancer Intergroup, that is, at least a 50% reduction of a pretreatment sample of 70 kU/L or greater. The value of CA125 in posttherapy surveillance is less clear. Although a prospective randomized trial concluded that early administration of chemotherapy based on increasing CA125 levels had no effect on survival, European Group on Tumor Markers state that monitoring with CA125 in this situation should occur, especially if the patient is a candidate for secondary cytoreductive surgery. Conclusions At present, CA125 remains the most important biomarker for epithelial ovarian cancer, excluding tumors of mucinous origin.

Published
2015

14. Alpha-fetoprotein detection of hepatocellular carcinoma leads to a standardized analysis of dynamic AFP to improve screening based detection

Author

Bird, Thomas G., Dimitropoulou, Polyxeni, M Turner, Rebecca, Jenks, Sara, Cusack, Pearce, Hey, Shiying, Blunsum, Andrew, Kelly, Sarah, Sturgeon, Catharine M, Hayes, Peter C., and Bird, Sheila M

Subjects
RC0254, RZ, lcsh:R, lcsh:Medicine, lcsh:Q, lcsh:Science, neoplasms, digestive system diseases
Abstract

Detection of hepatocellular carcinoma (HCC) through screening can improve outcomes. However, HCC surveillance remains costly, cumbersome and suboptimal. We tested whether and how serum Alpha-Fetoprotein (AFP) should be used in HCC surveillance. Record linkage, dedicated pathways for management and AFP data-storage identified i) consecutive highly characterised cases of HCC diagnosed in 2009–14 and ii) a cohort of ongoing HCC-free patients undergoing regular HCC surveillance from 2009. These two well-defined Scottish patient cohorts enabled us to test the utility of AFP surveillance. Of 304 cases of HCC diagnosed over 6 years, 42% (129) were identified by a dedicated HCC surveillance programme. Of these 129, 47% (61) had a detectable lesion first identified by screening ultrasound (US) but 38% (49) were prompted by elevated AFP. Despite pre-HCC diagnosis AFP >20kU/L being associated with poor outcome, ‘AFP-detected’ tumours were offered potentially curative management as frequently as ‘US-detected’ HCCs; and had comparable survival. Linearity of serial log10-transformed AFPs in HCC cases and in the screening ‘HCC-free’ cohort (n = 1509) provided indicators of high-risk AFP behaviour in HCC cases. An algorithm was devised in static mode, then tested dynamically. A case/control series in hepatitis C related disease demonstrated highly significant detection (p

Published
2016

17. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer Updated Guidelines From the European Group on Tumor Markers

Author

Soletormos, Gyorgy, Duffy, Michael J., Abu Hassan, Suher Othman, Verheijen, Rene H. M., Tholander, Bengt, Bast, Robert C., Jr., Gaarenstroom, Katja N., Sturgeon, Catharine M., Bonfrer, Johannes M., Petersen, Per Hyltoft, Troonen, Hugo, CarloTorre, Gian, Kulpa, Jan Kanty, Tuxen, Malgorzata K., Molina, Raphael, Soletormos, Gyorgy, Duffy, Michael J., Abu Hassan, Suher Othman, Verheijen, Rene H. M., Tholander, Bengt, Bast, Robert C., Jr., Gaarenstroom, Katja N., Sturgeon, Catharine M., Bonfrer, Johannes M., Petersen, Per Hyltoft, Troonen, Hugo, CarloTorre, Gian, Kulpa, Jan Kanty, Tuxen, Malgorzata K., and Molina, Raphael

Abstract

Objective:To present an update of the European Group on Tumor Markers guidelines for serum markers in epithelial varian cancer. Methods: Systematic literature survey from 2008 to 2013. The articles were evaluated by level of evidence and strength of recommendation. Results: Because of its low sensitivity (50-62% for early stage epithelial ovarian cancer) and limited specificity (94-98.5%), cancer antigen (CA) 125 (CA125) is not recommended as a screening test in asymptomatic women. The Risk of Malignancy Index, which includes CA125, transvaginal ultrasound, and menopausal status, is recommended for the differential diagnosis of a pelvic mass. Because human epididymis protein 4 has been reported to have superior specificity to CA125, especially in premenopausal women, it may be considered either alone or as part of the risk of ovarian malignancy algorithm, in the differential diagnosis of pelvic masses, especially in such women. CA125 should be used to monitor response to first-line chemotherapy using the previously published criteria of the Gynecological Cancer Intergroup, that is, at least a 50% reduction of a pretreatment sample of 70 kU/L or greater. The value of CA125 in posttherapy surveillance is less clear. Although a prospective randomized trial concluded that early administration of chemotherapy based on increasing CA125 levels had no effect on survival, European Group on Tumor Markers state that monitoring with CA125 in this situation should occur, especially if the patient is a candidate for secondary cytoreductive surgery. Conclusions: At present, CA125 remains the most important biomarker for epithelial ovarian cancer, excluding tumors of mucinous origin.

Published
2016
Full Text
View/download PDF

18. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers

Author

Sturgeon, Catharine M., Duffy, Michael J., Stenman, Ulf-Håkan, Lilja, Hans, Brünner, Nils, Chan, Daniel W., Babaian, Richard, Bast, Robert C., Dowell, Barry, Esteva, Francisco J., Haglund, Caj, Harbeck, Nadia, Hayes, Daniel F., Holten-Andersen, Mads Nikolaj, Klee, George G, Lamerz, Rolf, Looijenga, Leendert H, Molina, Rafael, Nielsen, Hans Jørgen, Rittenhouse, Harry, Semjonow, Axel, Shih, Ie-Ming, Sibley, Paul, Sölétormos, György, Stephan, Carsten, Sokoll, Lori, Hoffman, Barry R., Diamandis, Eleftherios P., Sturgeon, Catharine M, Duffy, Michael J, Chan, Daniel W, Bast, Robert C, Esteva, Francisco J, Hayes, Daniel F, Holten-Andersen, Mads, Hoffman, Barry R, Diamandis, Eleftherios P, NN, NN, Sturgeon, Catharine M., Duffy, Michael J., Stenman, Ulf-Håkan, Lilja, Hans, Brünner, Nils, Chan, Daniel W., Babaian, Richard, Bast, Robert C., Dowell, Barry, Esteva, Francisco J., Haglund, Caj, Harbeck, Nadia, Hayes, Daniel F., Holten-Andersen, Mads Nikolaj, Klee, George G, Lamerz, Rolf, Looijenga, Leendert H, Molina, Rafael, Nielsen, Hans Jørgen, Rittenhouse, Harry, Semjonow, Axel, Shih, Ie-Ming, Sibley, Paul, Sölétormos, György, Stephan, Carsten, Sokoll, Lori, Hoffman, Barry R., Diamandis, Eleftherios P., Sturgeon, Catharine M, Duffy, Michael J, Chan, Daniel W, Bast, Robert C, Esteva, Francisco J, Hayes, Daniel F, Holten-Andersen, Mads, Hoffman, Barry R, Diamandis, Eleftherios P, and NN, NN

Abstract

Udgivelsesdato: 2008-Dec, BACKGROUND: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. METHODS: Published reports relevant to use of tumor markers for 5 cancer sites--testicular, prostate, colorectal, breast, and ovarian--were critically reviewed. RESULTS: For testicular cancer, alpha-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. alpha-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 microg/L. In colorectal cancer, carcinoembryonic antigen is recommended (with some caveats) for prognosis determination, postoperative surveillance, and therapy monitoring in advanced disease. Fecal occult blood testing may be used for screening asymptomatic adults 50 years or older. For breast cancer, estrogen and progesterone receptors are mandatory for predicting response to hormone therapy, human epidermal growth factor receptor-2 measurement is mandatory for predicting response to trastuzumab, and urokinase plasminogen activator/plasminogen activator inhibitor 1 may be used for determining prognosis in lymph node-negative patients. CA15-3/BR27-29 or carcinoembryonic antigen may be used for therapy monitoring in advanced disease. CA125 is recommended (with transvaginal ultrasound) for early detection of ovarian cancer in women at high risk for this disease. CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therap

Published
2008

20. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers

Author

Sölétormos, György, primary, Duffy, Michael J., additional, Othman Abu Hassan, Suher, additional, Verheijen, René H.M., additional, Tholander, Bengt, additional, Bast, Robert C., additional, Gaarenstroom, Katja N., additional, Sturgeon, Catharine M., additional, Bonfrer, Johannes M., additional, Petersen, Per Hyltoft, additional, Troonen, Hugo, additional, CarloTorre, Gian, additional, Kanty Kulpa, Jan, additional, Tuxen, Malgorzata K., additional, and Molina, Raphael, additional

Published
2016
Full Text
View/download PDF

24. Design of Tumor Biomarker-Monitoring Trials : A Proposal by the European Group on Tumor Markers

Author

Soletormos, Gyorgy, Duffy, Michael J., Hayes, Daniel F., Sturgeon, Catharine M., Barak, Vivian, Bossuyt, Patrick M., Diamandis, Eleftherios P., Gion, Massimo, Hyltoft-Petersen, Per, Lamerz, Rolf M., Nielsen, Dorte L., Sibley, Paul, Tholander, Bengt, Tuxen, Malgorzata K., Bonfrer, Johannes M. G., Soletormos, Gyorgy, Duffy, Michael J., Hayes, Daniel F., Sturgeon, Catharine M., Barak, Vivian, Bossuyt, Patrick M., Diamandis, Eleftherios P., Gion, Massimo, Hyltoft-Petersen, Per, Lamerz, Rolf M., Nielsen, Dorte L., Sibley, Paul, Tholander, Bengt, Tuxen, Malgorzata K., and Bonfrer, Johannes M. G.

Abstract

A major application of tumor biomarkers is in serial monitoring of cancer patients, but there are no published guidelines on how to evaluate biomarkers for this purpose. The European Group on Tumor Markers has convened a multidisciplinary panel of scientists to develop guidance on the design of such monitoring trials. The panel proposes a 4-phase model for biomarker-monitoring trials analogous to that in use for the investigation of new drugs. In phase I, biomarker kinetics and correlation with tumor burden are assessed. Phase II evaluates the ability of the biomarker to identify, exclude, and/or predict a change in disease status. In phase III, the effectiveness of tumor biomarker guided intervention is assessed by measuring patient outcome in randomized trials. Phase IV consists of an audit of the long-term effects after biomarker monitoring has been included into standard patient care. Systematic well-designed evaluations of biomarkers for monitoring may provide a stronger evidence base that might enable their earlier use in evaluating responses to cancer therapy.

Published
2013
Full Text
View/download PDF

25. Colaboradores

Author

Ahmed, S. Faisal, Ah-Moye, David, Arya, Roopen, Ayling, Ruth M., Badminton, Michael N., Bayly, Graham R., Belsey, Sarah, Berry, Robin, Bindoff, Laurence A., Bjarnason, Ingvar T., Bomford, Adrian, Bruce, Helen, Carragher, Fiona, Chadwick, Carrie, Champion, Mike, Cundy, Timothy, Davies, Ceinwen, Davies, Teifion, Davies, Zoe, Dawnay, Anne, Dayan, Colin M., Dear, James W., East, James E., Elder, George H., Flanagan, Robert J., Frewin, Rebecca, Galtrey, Clare M., Gillen, Philip, Goodall, Roberta, Goody, Joanne, Grey, Andrew, Hallworth, Mike, Hart, Paul, Hayward, Peter, Howlett, Trevor A., Htut, Min, Jones, Jeremy G., Keir, Geoffrey, Labib, Mourad H., Lapsley, Marta, Launiainen, Terhi, Levy, Miles J., Loughrey, Clodagh M., McNeilly, Jane D., Makanjuola, David, Marshall, William J., Miell, John, Okosieme, Onyebuchi E., Paviour, Dominic C., Penney, Michael D., Rees, David C., Reid, Ian R., Riches, Pamela G., Ross, Leslie D., Seetho, Ian W., Sheldon, Joanna, Sherwood, Roy A., Sturgeon, Catharine M., Taylor, Peter, Wassif, Wassif S., Wheeler, Rachel D., Wilding, John P.H., Wile, David B., and Young, Ian S.

Published
2016

26. Design of Tumor Biomarker–Monitoring Trials: A Proposal by the European Group on Tumor Markers

Author

Sölétormos, György, primary, Duffy, Michael J, primary, Hayes, Daniel F, primary, Sturgeon, Catharine M, primary, Barak, Vivian, primary, Bossuyt, Patrick M, primary, Diamandis, Eleftherios P, primary, Gion, Massimo, primary, Hyltoft-Petersen, Per, primary, Lamerz, Rolf M, primary, Nielsen, Dorte L, primary, Sibley, Paul, primary, Tholander, Bengt, primary, Tuxen, Malgorzata K, primary, and Bonfrer, Johannes MG, primary

Published
2013
Full Text
View/download PDF

27. Translation: Roadmap for Harmonization of Clinical Laboratory Measurement Procedures

Author

Miller, W. Greg, primary, Myers, Gary L., additional, Gantzer, Mary Lou, additional, Kahn, Stephen E., additional, Schönbrunner, E. Ralf, additional, Thienpont, Linda M., additional, Bunk, David M., additional, Christenson, Robert H., additional, Eckfeldt, John H., additional, Lo, Stanley F., additional, Nübling, C. Micha, additional, and Sturgeon, Catharine M., additional

Published
2012
Full Text
View/download PDF

28. Roadmap for Harmonization of Clinical Laboratory Measurement Procedures

Author

Greg Miller, W, primary, Myers, Gary L, primary, Lou Gantzer, Mary, primary, Kahn, Stephen E, primary, Schönbrunner, E Ralf, primary, Thienpont, Linda M, primary, Bunk, David M, primary, Christenson, Robert H, primary, Eckfeldt, John H, primary, Lo, Stanley F, primary, Nübling, C Micha, primary, and Sturgeon, Catharine M, primary

Published
2011
Full Text
View/download PDF

31. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

Author

Sturgeon, Catharine M, primary, Duffy, Michael J, primary, Hofmann, Barry R, primary, Lamerz, Rolf, primary, Fritsche, Herbert A, primary, Gaarenstroom, Katja, primary, Bonfrer, Johannes, primary, Ecke, Thorsten H, primary, Grossman, H Barton, primary, Hayes, Peter, primary, Hoffmann, Ralf-Thorsten, primary, Lerner, Seth P, primary, Löhe, Florian, primary, Louhimo, Johanna, primary, Sawczuk, Ihor, primary, Taketa, Kazuhisa, primary, and Diamandis, Eleftherios P, primary

Published
2010
Full Text
View/download PDF

33. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

Author

Sturgeon, Catharine M, primary, Duffy, Michael J, primary, Stenman, Ulf-Håkan, primary, Lilja, Hans, primary, Brünner, Nils, primary, Chan, Daniel W, primary, Babaian, Richard, primary, Bast, Robert C, primary, Dowell, Barry, primary, Esteva, Francisco J, primary, Haglund, Caj, primary, Harbeck, Nadia, primary, Hayes, Daniel F, primary, Holten-Andersen, Mads, primary, Klee, George G, primary, Lamerz, Rolf, primary, Looijenga, Leendert H, primary, Molina, Rafael, primary, Nielsen, Hans Jørgen, primary, Rittenhouse, Harry, primary, Semjonow, Axel, primary, Shih, Ie-Ming, primary, Sibley, Paul, primary, Sölétormos, György, primary, Stephan, Carsten, primary, Sokoll, Lori, primary, Hoffman, Barry R, primary, and Diamandis, Eleftherios P, primary

Published
2008
Full Text
View/download PDF

35. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Clinical Practice: Quality Requirements1

Author

Sturgeon, Catharine M, primary, Hoffman, Barry R, primary, Chan, Daniel W, primary, Ch'ng, Soo-Ling, primary, Hammond, Elizabeth, primary, Hayes, Daniel F, primary, Liotta, Lance A, primary, Petricoin, Emmanuel F, primary, Schmitt, Manfred, primary, Semmes, O John, primary, Söletormos, Györg, primary, van der Merwe, Elena, primary, and Diamandis, Eleftherios P, primary

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results